The short version of bioavailability fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-02-13 and is reviewed periodically as new material appears.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
== Functions == Lpp, along with another OmpA-like lipoprotein called Pal/OprL (P0A912), maintains the stability of the cell envelope by attaching the outer membrane to the cell wall. Lpp has been proposed as a virulence factor of Yersinia pestis, the cause of plague. Y. pestis needs lpp for maximum survival in macrophages and to efficiently kill mouse models of bubonic and pneumonic plague.
== External links == Richard L.M. Synge on Nobelprize.org Synge's Nobel Lecture Applications of Partition Chromatography Sidney Elsden (21 June 2016), Richard Laurence Millington Synge (PDF), archived from the original (PDF) on 29 October 2007, retrieved 17 October 2007
== Contraindications == EMP is contraindicated when used in children, patients hypersensitive to estrogens or nitrogen mustards, those with peptic ulcer (an ulcer in the digestive tract), those with severely compromised liver function, those with weak heart muscle (also known as myocardial insufficiency) and those with thromboembolic disorders or complications related to fluid retention.
Necrophagous flies have several traits and adaptations that facilitate their feeding behavior. For example, blow flies and flesh flies have a well-developed sense of smell and are highly mobile. This enables them to rapidly detect and locate carrion. Also, flesh flies and some blow flies lay larvae instead of eggs. This gives these flies a competitive advantage over other slower-developing, egg-laying species. In addition, blow flies, flesh flies, muscid flies and black soldier flies have many defenses against the pathogens and toxins found in carrion. These include a protective lining in their midgut, antibiotic-producing microbiota species, and a large number of pattern recognition receptors, lysozymes, antimicrobial peptides and detoxification enzymes. The diversity and abundance of necrophagous fly species vary geographically and seasonally. For example, Chrysomya species are present in subtropical regions of the USA but are rare in most of Canada. This geographic variation is attributable to factors such as soil type and meteorological conditions, and the effects these have on carrion decomposition. Whether urbanization affects fly species richness is open to dispute. Seasonally, many necrophagous fly species are observed in higher abundance in summer, but Thyreophora cynophila is more active in winter. Flies play a critical role in forensic science as they are often the first insects to discover and colonize human remains. Blow flies can arrive within minutes and begin laying eggs in the nose, mouth and other openings.
Sources: en.wikipedia.org
Tandem affinity purification (TAP) is an immunoprecipitation-based purification technique for studying protein–protein interactions. The goal is to extract from a cell only the protein of interest, in complex with any other proteins it interacted with. TAP uses two types of agarose beads that bind to the protein of interest and that can be separated from the cell lysate by centrifugation, without disturbing, denaturing or contaminating the involved complexes. To enable the protein of interest to bind to the beads, it is tagged with a designed piece, the TAP tag. The original TAP method involves the fusion of the TAP tag to the C-terminus of the protein under study. The TAP tag consists of three components: a calmodulin binding peptide (CBP), TEV protease cleavage site, and two Protein A domains, which bind tightly to IgG (making a TAP tag a type of epitope tag). Many other tag/bead/eluent combinations have been proposed since the TAP principle was first published.
The convergent orientation of the catalytic triad in the active site of serine and cysteine proteases independently in over 20 enzyme superfamilies. The use of an N-terminal threonine for proteolysis. The existence of distinct families of carbonic anhydrase is believed to illustrate convergent evolution. The use of (Z)-7-dodecen-1-yl acetate as a sex pheromone by the Asian elephant (Elephas maximus) and by more than 100 species of Lepidoptera. The biosynthesis of plant hormones such as gibberellin and abscisic acid by different biochemical pathways in plants and fungi. The protein prestin that drives the cochlea amplifier and confers high auditory sensitivity in mammals, shows numerous convergent amino acid replacements in bats and dolphins, both of which have independently evolved high frequency hearing for echolocation. This same signature of convergence has also been found in other genes expressed in the mammalian cochlea The repeated independent evolution of nylonase in two different strains of Flavobacterium and one strain of Pseudomonas. The myoglobin from the abalone Sulculus diversicolor has a different structure from normal myoglobin but serves a similar function — binding oxygen reversibly. "The molecular weight of Sulculus myoglobin is 41kD, 2.5 times larger than other myoglobins." Moreover, its amino acid sequence has no homology with other invertebrate myoglobins or with hemoglobins, but is 35% homologous with human indoleamine dioxygenase (IDO), a vertebrate tryptophan-degrading enzyme. It does not share similar function with IDO.
The collection grew slowly and suffered another major fire in 1851, which destroyed two-thirds of Jefferson's original books. The Library of Congress faced space shortages, understaffing, and lack of funding, until the American Civil War increased the importance of legislative research to meet the demands of a growing federal government. In 1870, the library gained the right to receive two copies of every copyrightable work printed in the United States; it also built its collections through acquisitions and donations. Between 1890 and 1897, a new library building, now the Thomas Jefferson Building, was constructed. Two additional buildings, the John Adams Building (opened in 1939) and the James Madison Memorial Building (opened in 1980), were later added. The LC's Congressional Research Service provides objective non-partisan research to Congress to assist it in passing legislation. The library is open to the public for research, although only members of Congress, their staff, and library employees may borrow materials for use outside the library.
==== Inflammatory bowel diseases ==== There is a genetic association between GPX4 and Crohn's disease. Subsequent study found that small intestinal epithelial cells (IECs) from Crohn's disease patient samples show reduced GPX4 expression and activity and lipid peroxidation. The same study found that dietary lipids in Western diets such as the PUFA arachidonic acid can trigger enteritis resembling Crohn's disease in a mouse model.
Tralokinumab sold under the brand names Adtralza (EU/UK) and Adbry (US) among others, is a human monoclonal antibody used for the treatment of atopic dermatitis. Tralokinumab targets the cytokine interleukin 13. The most common side effects include upper respiratory tract infections (colds and other infections of the nose and throat), reactions at the injection site, and redness and discomfort in the eye. Tralokinumab was approved for medical use in the European Union and in the United Kingdom in June 2021. It was approved for medical use in the United States in December 2021. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Sources: en.wikipedia.org
Some raids were met with 100% of the fighters dispatched successfully engaging their targets, while German aircraft returned home over half the time never having seen the enemy. It is for this reason that Churchill credits Chain Home with winning the Battle.
== Adaptive immune response == In order to understand the links between the innate immune response and the adaptive immune response to help substantiate an adjuvant function in enhancing adaptive immune responses to the specific antigen of a vaccine, the following points should be considered:
=== Appeal === In January 2024, Letby applied to the Court of Appeal for permission to challenge her convictions, but this was refused by a single judge. She renewed her application, and at a three‑day hearing in April 2024 her legal team advanced four grounds of appeal relating to the trial judge's rulings. In May 2024, a panel comprising Dame Victoria Sharp, Lord Justice Holroyde and Mrs Justice Lambert refused permission to appeal. As part of the appeal, Letby's counsel, Ben Myers, again challenged the admission of evidence from paediatrician Evans, arguing that it should have been excluded on the basis that Evans had been "dogmatic and biased". The appeal judges rejected this, finding that Evans did not lack impartiality, was suitably qualified to give expert evidence, and that it was for the jury to assess its weight. A second ground of appeal concerned the medical evidence relating to alleged fatal air injections, which the defence described as "very weak". A third ground argued that the trial judge had erred in directing the jury that they could convict even if they were uncertain about the precise method used in each case. The final ground alleged that the judge had failed to investigate a question of juror impartiality. All four grounds were dismissed, with the Court concluding in its written judgement that the trial had been "thoughtful, fair, comprehensive and correct" and that none of the challenges raised by the defence were "arguable".
=== Extraction === Lactobacillic acid can be isolated from the lipids of bacteria, as used by the working group during the discovery. First, hydrolysis (saponification) of the phospholipids or triglycerides is carried out, releasing the fatty acid bound as an ester. Since other fatty acids are present in addition to lactobacillic acid, separation is then carried out using urea extraction crystallization or column chromatography. The fractional crystallization process can also be used.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.